https://www.selleckchem.com/pr....oducts/Aloxistatin.h
TMEcluster-B associated with poor overall survival (p less then 0.001; HR 2.629) and recurrence free survival (p=0.012; HR 1.87 in ccRCC validation cohort. TMEcluster-B cases had worse treatment response (p=0.009), overall survival (p less then 0.001; HR 2.223) and progression free survival (p=0.015; HR 2.7762) in metastatic ccRCC cohort. The predictive accuracy of International Metastatic Database Consortium risk score was improved after incorporation of TME clusters. CONCLUSIONS TMEcluster-A featured increased mast cells infiltr
Curtir
Comentario
Compartilhar
